FDA is investigating risk of severe hypocalcemia in dialysis patients taking Prolia (denosumab). After an interim safety
Tweet Content
FDA is investigating risk of severe hypocalcemia in dialysis patients taking Prolia (denosumab). After an interim safety data review reports of hypocalcemia w/ advanced CKD. Monitor Ca, use Ca & vit D supplements. Await further FDA information https://t.co/6pMwBPFJJr https://t.co/lTdpX0FQwj
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off